Recent Progress on Primary Central Nervous System Lymphoma—From Bench to Bedside
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extra-nodal lymphoma. The high relapse rate of PCNSL remains a major challenge to the hematologists, even though patients exhibit high sensitivity to the methotrexate-based chemotherapeutic regimens. Recently, the advent of Bruton’...
Main Authors: | Liang Shao, Chengshi Xu, Huijing Wu, Muhammad Jamal, Shan Pan, Sirui Li, Fei Chen, Ding Yu, Kui Liu, Yongchang Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.689843/full |
Similar Items
-
Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib
by: Cheng Q, et al.
Published: (2021-05-01) -
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
by: Yoshiko Okita, et al.
Published: (2021-04-01) -
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
by: Kamil D. Kaplanov
Published: (2021-08-01) -
Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01) -
Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
by: Girard J, et al.
Published: (2019-09-01)